Investment Analysts’ Recent Ratings Changes for Inozyme Pharma (INZY)

A number of research firms have changed their ratings and price targets for Inozyme Pharma (NASDAQ: INZY):

• 1/13/2025 – Inozyme Pharma had its price target lowered by analysts at Wells Fargo & Company from $14.00 to $11.00. They now have an “overweight” rating on the stock.
• 1/13/2025 – Inozyme Pharma had its price target lowered by analysts at Piper Sandler from $43.00 to $30.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Inozyme Pharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.
• 1/10/2025 – Inozyme Pharma had its price target raised by analysts at HC Wainwright from $14.00 to $16.00. They now have a “buy” rating on the stock.
• 12/12/2024 – Inozyme Pharma is now covered by analysts at Raymond James. They set an “outperform” rating and a $26.00 price target on the stock.

Inozyme Pharma Trading Down 3.0 %

Shares of Inozyme Pharma stock traded down $0.05 on Wednesday, reaching $1.47. The company had a trading volume of 195,012 shares, compared to its average volume of 896,826. The firm has a market cap of $94.11 million, a price-to-earnings ratio of -0.94 and a beta of 1.35. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The firm’s 50-day moving average price is $2.91 and its two-hundred day moving average price is $4.34. Inozyme Pharma, Inc. has a 1 year low of $1.45 and a 1 year high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. As a group, research analysts predict that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current fiscal year.

Institutional Trading of Inozyme Pharma

Several institutional investors and hedge funds have recently made changes to their positions in INZY. JPMorgan Chase & Co. raised its stake in shares of Inozyme Pharma by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock valued at $151,000 after acquiring an additional 6,851 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Inozyme Pharma in the 3rd quarter worth $64,000. Barclays PLC grew its position in shares of Inozyme Pharma by 261.4% during the 3rd quarter. Barclays PLC now owns 76,730 shares of the company’s stock worth $401,000 after buying an additional 55,497 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Inozyme Pharma by 1.7% during the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock valued at $6,126,000 after buying an additional 19,499 shares during the period. Finally, Jane Street Group LLC raised its holdings in shares of Inozyme Pharma by 7.5% in the third quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock valued at $259,000 after acquiring an additional 3,443 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.